One Patient in Ten Pays for the Whole Dialysis Clinic
Medicare covers dialysis for nearly everyone who needs it, at rates near cost. The entire profit of a half million patient industry is concentrated in the small minority still on commercial insurance.
A Federal Promise From 1972
Kidney failure is the one diagnosis that entitles almost every American to Medicare regardless of age, a promise Congress made in 1972 when dialysis was new and the patient population was small. Today more than half a million Americans have end stage kidney disease, most requiring three treatments a week for life or until transplant, and the entitlement that made treatment universal also fixed the industry's economics: the government sets a bundled payment per treatment, and that rate sits near, and for many clinics below, the cost of delivering it.
The Cross Subsidy That Runs the Industry
The industry survives on the patients Medicare does not yet cover. Under federal coordination rules, a patient with employer group insurance keeps that coverage as primary payer for roughly the first thirty months of dialysis before Medicare takes over. Commercial insurers pay multiples of the Medicare rate for the identical treatment, often three to four times, sometimes more. The arithmetic that follows is stark.
| Payer | Share of patients | Contribution |
|---|---|---|
| Medicare and Medicaid | Roughly 90 percent | Near break even or loss making |
| Commercial insurance | Roughly 10 percent | Essentially all of the profit |
Nine patients in ten are treated at close to cost. The business model is the tenth patient, and every strategic decision in the industry traces back to finding, keeping, and extending that patient's commercial coverage.
Why Two Chains Run Most of It
Two companies operate on the order of seventy percent of American clinics. Scale fits the reimbursement structure: when the dominant payer sets one price, the winner is whoever has the lowest cost per treatment, and chains squeeze costs through purchasing power over dialysis machines and drugs, standardized staffing models, and dense networks that keep chairs full. Density also matters clinically and commercially, because patients pick clinics near home and referring nephrologists, many of whom hold joint venture stakes in the clinics, keep their patients inside the network.
The Frictions the Model Creates
A cross subsidy this steep invites conflict at the boundary. Insurers try to shorten the commercial window, and the industry funds charitable premium assistance that helps patients stay on commercial plans, a practice critics call self dealing and the industry calls access. A 2021 ballot fight in California over clinic staffing rules was widely read as a proxy war over these economics. Meanwhile policy is drifting against the clinic model itself: payment experiments now reward home dialysis and transplantation, both cheaper for the government and both subtractive for a business built on in center chairs.
The Bottom Line
Dialysis is a case study in payer mix as destiny. A universal entitlement set the floor price near cost, coordination rules created a small commercially insured minority paying several times more, and an entire consolidated industry organized itself around defending that sliver. When one customer sets prices administratively and another negotiates, the profit pools where the negotiation is, and everything else follows from where the line between them is drawn.